Physician profile
Anas Noman
NPI 1023540838
$13,049.33
in general payments reported to CMS, 2019-2025
19 companies · $6,116 in 2025
The $6,116 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $245 · 2023: $4,184 · 2024: $2,383 · 2025: $6,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,702 · Travel and Lodging: $5,532 · Grant: $1,126 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,701.97 |
| Travel and Lodging | $5,532.36 |
| Grant | $1,126.44 |
| Education | $322.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,023.33 | 2023-2025 | Supera, Triclip, Mitraclip |
| Edwards Lifesciences Corporation | $3,440.33 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $2,401.57 | 2023-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Boston Scientific Corporation | $1,526.52 | 2023-2024 | Avvigo Guidance System, Rotablator Rotational Atherectomy System Console Kit, Watchman |
| W. L. Gore & Associates, INC. | $471.10 | 2025 | Gore Cardioform Septal Occluder |
| Amgen INC. | $134.40 | 2022 | |
| Stryker Corporation | $126.60 | 2025 | Flowtriever |
| Astrazeneca Pharmaceuticals LP | $121.81 | 2021 | |
| Shockwave Medical, INC | $111.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.14 | 2022 | |
| Inari Medical, INC. | $104.33 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Philips North America LLC | $90.15 | 2025 | Ice 3d |
| Bayer Healthcare Pharmaceuticals INC. | $86.53 | 2025 | |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Chiesi USA, INC. | $83.64 | 2024 | Kengreal |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $66.39 | 2023-2025 | |
| Scpharmaceuticals INC. | $30.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2025 | Jardiance |
| Novo Nordisk INC | $14.42 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Noman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.